🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS

Recruitingn/aAges 18 Years - anyAllFondazione IRCCS Policlinico San Matteo di Pavia
NCT06886672 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm of the pleural mesothelium, mainly associated to asbestos exposure, still lacking effective therapies. Asbestos is a not-mutagenic agent: its nanosized fibres directly interact with tyrosine kinases (TKs) (e.g. EGFR) and may induce inappropriate receptor dimerization and activation, in absence of activating somatic mutations. TK receptor activation initiates cell signaling cascades and carcinogenesis. Asbestos, thus, induces the generation of an inflammatory immunosuppressive microenvironment that may support tumor growth in individuals with genetic predisposition (2). Consequently, the lack of actionable tumor targets together with the heterogeneous stroma, support the failure of modern drugs, both TK and immune-checkpoint inhibitors (TKIs, ICIs). In this complex context, the role of germline changes in MPM remains

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria Cohort A: * Patient with a documented diagnosis of MPM (any disease stage and independently from chemo line treatment) * Age ≥ 18 years (there is no upper age limit). * Patient who gives their informed consent to participate in the study Exclusion Criteria Cohort A: * No exclusion criteria Inclusion Criteria Cohort B: * Former asbestos exposed healthy subjects * Age ≥ 18 years (there is no upper age limit). * Subject who gives their informed consent to participate in the study Exclusion Criteria Cohort B: * No exclusion criteria
💊

What it tests

  • Not listed
📍

Where

2 sites
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
IRCCS Istituti Clinici Maugeri, Medicina del Lavoro
Pavia, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy